[1]
International Classification of Sleep Disorders, 3rd ed. American Academy of Sleep Medicine, Darien, IL 2014.
[2]
The international classification of sleep disorders diagnostic and coding manual 2nd ed. American Academy of Sleep Medicine, Westchester, IL 2005.
[3]
Guilleminault C., Pelayo R.: Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up. Paediatr Drugs 2000; 2: 1–9.
[4]
Nevsimalova S.: Narcolepsy in childhood. Sleep Med Rev 2009; 13: 169–180.
[5]
Schenck C.H., Bassetti C.L., Arnulf I., et al.: English translations of the first clinical reports on narcolepsy and cataplexy by Westphal and Gelineau in the late 19th century, with commentary. J Clin Sleep Med 2007; 3: 301–311.
[6]
Gélineau J.: De la narcolepsie. Gaz Hôp Civil Milit 1880; 53: 626–628, 635–637.
[7]
Daniels L.: Narcolepsy. Medicine 1934; 13: 122.
[8]
Mignot E.: A hundred years of narcolepsy research. Arch Ital Biol 2001; 139: 207–220.
[9]
Yoss R.E., Daly D.D.: Criteria for the diagnosis of the narcoleptic syndrome. Proc Staff Meet Mayo Clin 1957; 32: 320–328.
[10]
Vogel G.: Studies in psychophysiology of dreams. III. The dream of narcolepsy. Arch Gen Psychiatry 1960; 3: 421–428.
[11]
Ohayon M.M., Ferini-Strambi L., Plazzi G., et al.: How age influences the expression of narcolepsy. J Psychosom Res 2005; 59: 399–405.
[12]
Nevsimalova S., Buskova J., Kemlink D., et al.: Does age at the onset of narcolepsy influence the course and severity of the disease? Sleep Med 2009; 10: 967–972.
[13]
Dauvilliers Y., Montplaisir J., Molinari N., et al.: Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001; 57: 2029–2033.
[14]
Thorpy M.: Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med 2001; 2: 5–17.
[15]
Ohayon M.M., Priest R.G., Zulley J., et al.: Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 2002; 58: 1826–1833.
[16]
Hublin C., Kaprio J., Partinen M., et al.: The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann Neurol 1994; 35: 709–716.
[17]
Oksenberg J., Amar A., Cohen N., et al.: HLA-D „BG” in Israel. A Japanese related allele population and family study. Tissue Antigens 1983; 21: 271–280.
[18]
Lavie P., Peled R.: Narcolepsy is a rare disease in Israel. Sleep 1987; 10: 608–609.
[19]
Wilner A., Steinman L., Lavie P., et al.: Narcolepsy-cataplexy in Israeli Jews is associated exclusively with the HLA DR2 haplotype. A study at the serological and genomic level. Hum Immunol 1988; 21: 15-22.
[20]
Honda K.: Census of narcolepsy, cataplexy and sleep life among teenagers in Fujisawa City. Sleep Res 1979; 8.
[21]
Tashiro T., Kanbayashi T., Iijima S., et al.: An epidemiological study on prevalence of narcolepsy in Japanese. J Sleep Res 1992; 1.
[22]
Guilleminault C., Mignot E., Grumet F.C.: Familial patterns of narcolepsy. Lancet 1989; 2: 1376-1379.
[23]
Billiard M., Pasquie-Magnetto V., Heckman M., et al.: Family studies in narcolepsy. Sleep 1994; 17: 54-59.
[24]
Baraitser M., Parkes J.D.: Genetic study of narcoleptic syndrome. J Med Genet 1978; 15: 254-259.
[25]
Hayduk R., Flodman P., Spence M.A., et al.: HLA haplotypes, polysomnography, and pedigrees in a case series of patients with narcolepsy. Sleep 1997; 20: 850-857.
[26]
Nevsimalova S., Mignot E., Sonka K., et al.: Familial aspects of narcolepsy-cataplexy in the Czech Republic. Sleep 1997; 20: 1021-1026.
[27]
Maret S., Tafti M.: Genetics of narcolepsy and other major sleep disorders. Swiss Med Wkly 2005; 135: 662-665.
[28]
Mignot E.: Genetics of narcolepsy and other sleep disorders. Am J Hum Genet 1997; 60: 1289-1302.
[29]
Honda M., Honda Y., Uchida S., et al.: Monozygotic twins incompletely concordant for narcolepsy. Biol Psychiatry 2001; 49: 943-947.
[30]
Partinen M., Hublin C., Kaprio J., et al.: Twin studies in narcolepsy. Sleep 1994; 17: 13-16.
[31]
Pollmacher T., Schulz H., Geisler P., et al.: DR2-positive monozygotic twins discordant for narcolepsy. Sleep 1990; 13: 336-343.
[32]
Neely S., Rosenberg R., Spire J.P., et al.: HLA antigens in narcolepsy. Neurology 1987; 37: 1858-1860.
[33]
Mignot E., Lin L., Rogers W., et al.: Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001; 68: 686-699.
[34]
Rogers A.E., Meehan J., Guilleminault C., et al.: HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology 1997; 48: 1550-1556.
[35]
Saper C.B., Scammell T.E., Lu J.: Hypothalamic regulation of sleep and circadian rhythms. Nature 2005; 437: 1257-1263.
[36]
Sakurai T., Amemiya A., Ishii M., et al.: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573-585.
[37]
de Lecea L., Kilduff T.S., Peyron C., et al.: The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998; 95: 322-327.
[38]
Lin L., Faraco J., Li R., et al.: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365-376.
[39]
Chemelli R.M., Willie J.T., Sinton C.M., et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437-451.
[40]
John J., Wu M.F., Boehmer L.N., et al.: Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron 2004; 42: 619-634.
[41]
Mignot E., Nishino S., Sharp L.H., et al.: Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 1993; 13: 1057-1064.
[42]
Peterson P.C., Husain A.M.: Pediatric narcolepsy. Brain Dev 2008; 30: 609-623.
[43]
Thannickal T.C., Moore R.Y., Nienhuis R., et al.: Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-474.
[44]
Peyron C., Faraco J., Rogers W., et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-997.
[45]
Ripley B., Overeem S., Fujiki N., et al.: CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001; 57: 2253-2258.
[46]
Nishino S., Ripley B., Overeem S., et al.: Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 39-40.
[47]
Nishino S., Ripley B., Overeem S., et al.: Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001; 50: 381-388.
[48]
Mignot E., Lammers G.J., Ripley B., et al.: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553-1562.
[49]
Dalal M.A., Schuld A., Haack M., et al.: Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. Neurology 2001; 56: 1749-1751.
[50]
Kanbayashi T., Yano T., Ishiguro H., et al.: Hypocretin-1 (orexin-A) levels in human lumbar CSF in different age groups: infants to elderly persons. Sleep 2002; 25: 337-339.
[51]
Tsukamoto H., Ishikawa T., Fujii Y., et al.: Undetectable levels of CSF hypocretin-1 (orexin-A) in two prepubertal boys with narcolepsy. Neuropediatrics 2002; 33: 51-52.
[52]
Kubota H., Kanbayashi T., Tanabe Y., et al.: Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children. Sleep 2003; 26: 555-557.
[53]
Aran A., Lin L., Nevsimalova S., et al.: Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009; 32: 979-983.
[54]
Mahlios J., De la Herran-Arita A.K., Mignot E.: The autoimmune basis of narcolepsy. Curr Opin Neurobiol 2013; 23: 767-773.
[55]
Dale R.C.: Post-streptococcal autoimmune disorders of the central nervous system. Dev Med Child Neurol 2005; 47: 785-791.
[56]
Nevsimalova S., Jara C., Prihodova I., et al.: Clinical features of childhood narcolepsy. Can cataplexy be foretold? Eur J Paediatr Neurol 2011; 15: 320-325.
[57]
Han F., Lin L., Li J., et al.: Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic. Ann Neurol 2013; 73: 560.
[58]
Wijnans L., Lecomte C., de Vries C., et al.: The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31: 1246-1254.
[59]
Nohynek H., Jokinen J., Partinen M., et al.: AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012; 7: e33536.
[60]
Poli F., Overeem S., Lammers G.J., et al.: Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. Vaccine 2013; 31: 994-1007.
[61]
Overeem S., Black J.L., 3rd, Lammers G.J.: Narcolepsy: immunological aspects. Sleep Med Rev 2008; 12: 95-107.
[62]
Boehmer L.N., Wu M.F., John J., et al.: Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity. Exp Neurol 2004; 188: 292-299.
[63]
Hecht M., Lin L., Kushida C.A., et al.: Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy. Sleep 2003; 26: 809-810.
[64]
Dauvilliers Y., Abril B., Mas E., et al.: Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 2009; 73: 1333-1334.
[65]
Dauvilliers Y., Carlander B., Rivier F., et al.: Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004; 56: 905-908.
[66]
Lecendreux M., Maret S., Bassetti C., et al.: Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003; 12: 347-348.
[67]
Plazzi G., Poli F., Franceschini C., et al.: Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol 2008; 255: 1549-1554.
[68]
Schatzberg S.J., Cutter-Schatzberg K., Nydam D., et al.: The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med 2004; 18: 586-588.
[69]
Stores G.: Recognition and management of narcolepsy. Arch Dis Child 1999; 81: 519-524.
[70]
Vendrame M., Havaligi N., Matadeen-Ali C., et al.: Narcolepsy in children: a single-center clinical experience. Pediatr Neurol 2008; 38: 314-320.
[71]
Wise M.S., Lynch J.: Narcolepsy in children. Semin Pediatr Neurol 2001; 8: 198-206.
[72]
Okun M.L., Lin L., Pelin Z., et al.: Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002; 25: 27-35.
[73]
Silber M.H., Krahn L.E., Olson E.J., et al.: The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002; 25: 197-202.
[74]
Benca R.M.: Narcolepsy and excessive daytime sleepiness: diagnostic considerations, epidemiology, and comorbidities. J Clin Psychiatry 2007; 68 Suppl 13: 5-8.
[75]
Wise M.S.: Narcolepsy and other disorders of excessive sleepiness. Med Clin North Am 2004; 88: 597-610, vii-viii.
[76]
Kothare S.V., Kaleyias J.: Narcolepsy and other hypersomnias in children. Curr Opin Pediatr 2008; 20: 666-675.
[77]
Nevsimalova S., Pisko J., Buskova J., et al.: Narcolepsy: clinical differences and association with other sleep disorders in different age groups. J Neurol 2013; 260: 767-775.
[78]
Harsh J., Peszka J., Hartwig G., et al.: Night-time sleep and daytime sleepiness in narcolepsy. J Sleep Res 2000; 9: 309-316.
[79]
Scammell T.E.: The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol 2003; 53: 154-166.
[80]
Dahl R.E., Holttum J., Trubnick L.: A clinical picture of child and adolescent narcolepsy. J Am Acad Child Adolesc Psychiatry 1994; 33: 834-841.
[81]
Thorpy M.J.: Cataplexy associated with narcolepsy: epidemiology, pathophysiology and management. CNS Drugs 2006; 20: 43-50.
[82]
Krahn L.E., Lymp J.F., Moore W.R., et al.: Characterizing the emotions that trigger cataplexy. J Neuropsychiatry Clin Neurosci 2005; 17: 45-50.
[83]
Anic-Labat S., Guilleminault C., Kraemer H.C., et al.: Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999; 22: 77-87.
[84]
Serra L., Montagna P., Mignot E., et al.: Cataplexy features in childhood narcolepsy. Mov Disord 2008; 23: 858-865.
[85]
Overeem S., Mignot E., van Dijk J.G., et al.: Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001; 18: 78-105.
[86]
de Zambotti M., Pizza F., Covassin N., et al.: Facing emotions in narcolepsy with cataplexy: haemodynamic and behavioural responses during emotional stimulation. J Sleep Res 2014; 23: 432-440.
[87]
Pizza F., Franceschini C., Peltola H., et al.: Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain 2013; 136: 3787-3795.
[88]
Plazzi G., Pizza F., Palaia V., et al.: Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain 2011; 134: 3477-3489.
[89]
Kandt R.S., Emerson R.G., Singer H.S., et al.: Cataplexy in variant forms of Niemann-Pick disease. Ann Neurol 1982; 12: 284-288.
[90]
Parkes J.D.: Genetic factors in human sleep disorders with special reference to Norrie disease, Prader-Willi syndrome and Moebius syndrome. J Sleep Res 1999; 8 Suppl 1: 14-22.
[91]
Martinez-Rodriguez J.E., Lin L., Iranzo A., et al.: Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness. Sleep 2003; 26: 287-290.
[92]
Zarowski M., Steinborn B., Gurda B., et al.: Treatment of cataplexy in Niemann-Pick disease type C with the use of miglustat. Eur J Paediatr Neurol 2011; 15: 84-87.
[93]
Pedroso J.L., Fusao E.F., Ladeia-Frota C., et al.: Teaching video neuroimages: gelastic cataplexy as the first neurologic manifestation of Niemann-Pick disease type C. Neurology 2012; 79: e189.
[94]
Girard T.A., Cheyne J.A.: Timing of spontaneous sleep-paralysis episodes. J Sleep Res 2006; 15: 222-229.
[95]
Kales A., Cadieux R.J., Soldatos C.R., et al.: Narcolepsy-cataplexy. I. Clinical and electrophysiologic characteristics. Arch Neurol 1982; 39: 164-816.
[96]
Goode G.B.: Sleep paralysis. Arch Neurol 1962; 6: 228-234.
[97]
Guilleminault C., Pelayo R.: Narcolepsy in prepubertal children. Ann Neurol 1998; 43: 135-142.
[98]
Sturzenegger C., Bassetti C.L.: The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res 2004; 13: 395-406.
[99]
Stores G.: The protean manifestations of childhood narcolepsy and their misinterpretation. Dev Med Child Neurol 2006; 48: 307-310.
[100]
Plazzi G., Serra L., Ferri R.: Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev 2008; 12: 109-128.
[101]
Dauvilliers Y., Rompre S., Gagnon J.F., et al.: REM sleep characteristics in narcolepsy and REM sleep behavior disorder. Sleep 2007; 30: 844-849.
[102]
Vandeputte M., de Weerd A.: Sleep disorders and depressive feelings: a global survey with the Beck depression scale. Sleep Med 2003; 4: 343-345.
[103]
Chakravorty S.S., Rye D.B.: Narcolepsy in the older adult: epidemiology, diagnosis and management. Drugs Aging 2003; 20: 361-376.
[104]
Billiard M., Bassetti C., Dauvilliers Y., et al.: EFNS guidelines on management of narcolepsy. Eur J Neurol 2006; 13: 1035-1048.
[105]
Dahmen N., Becht J., Engel A., et al.: Prevalence of eating disorders and eating attacks in narcolepsy. Neuropsychiatr Dis Treat 2008; 4: 257-261.
[106]
Kotagal S., Krahn L.E., Slocumb N.: A putative link between childhood narcolepsy and obesity. Sleep Med 2004; 5: 147-150.
[107]
Peraita-Adrados R., Garcia-Penas J.J., Ruiz-Falco L., et al.: Clinical, polysomnographic and laboratory characteristics of narcolepsy-cataplexy in a sample of children and adolescents. Sleep Med 2011; 12: 24-27.
[108]
Chabas D., Foulon C., Gonzalez J., et al.: Eating disorder and metabolism in narcoleptic patients. Sleep 2007; 30: 1267-1273.
[109]
Baker T.L., Guilleminault C., Nino-Murcia G., et al.: Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. Sleep 1986; 9: 232-242.
[110]
Luc M.E., Gupta A., Birnberg J.M., et al.: Characterization of symptoms of sleep disorders in children with headache. Pediatr Neurol 2006; 34: 7-12.
[111]
Dahmen N., Kasten M., Wieczorek S., et al.: Increased frequency of migraine in narcoleptic patients: a confirmatory study. Cephalalgia 2003; 23: 14-19.
[112]
Dahmen N., Querings K., Grun B., et al.: Increased frequency of migraine in narcoleptic patients. Neurology 1999; 52: 1291-1293.
[113]
Littner M.R., Kushida C., Wise M., et al.: Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005; 28: 113-121.
[114]
Bradshaw D.A., Yanagi M.A., Pak E.S., et al.: Nightly sleep duration in the 2-week period preceding multiple sleep latency testing. J Clin Sleep Med 2007; 3: 613-619.
[115]
Hoddes E., Zarcone V., Smythe H., et al.: Quantification of sleepiness: a new approach. Psychophysiology 1973; 10: 431-436.
[116]
Johns M.W.: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-545.
[117]
Drake C., Nickel C., Burduvali E., et al.: The pediatric daytime sleepiness scale (PDSS): sleep habits and school outcomes in middle-school children. Sleep 2003; 26: 455-458.
[118]
Carskadon M.A., Dement W.C., Mitler M.M., et al.: Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986; 9: 519-524.
[119]
Nevsimalova S., Prihodova I., Kemlink D., et al.: REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy. Sleep Med 2007; 8: 784-786.
[120]
Kothare S.V., Kaleyias J.: The clinical and laboratory assessment of the sleepy child. Semin Pediatr Neurol 2008; 15: 61-69.
[121]
Arand D., Bonnet M., Hurwitz T., et al.: The clinical use of the MSLT and MWT. Sleep 2005; 28: 123-144.
[122]
Kotagal S., Hartse K.M., Walsh J.K.: Characteristics of narcolepsy in preteenaged children. Pediatrics 1990; 85: 205-209.
[123]
Mitler M.M., Doghramji K., Shapiro C.: The maintenance of wakefulness test: normative data by age. J Psychosom Res 2000; 49: 363-365.
[124]
Zandieh S., Ramgopal S., Khatwa U., et al.: The maintenance of wakefulness test in pediatric narcolepsy. Pediatr Neurol 2013; 48: 443-446.
[125]
Mignot E., Young T., Lin L., et al.: Nocturnal sleep and daytime sleepiness in normal subjects with HLA-DQB1*0602. Sleep 1999; 22: 347-352.
[126]
Dauvilliers Y., Arnulf I., Mignot E.: Narcolepsy with cataplexy. Lancet 2007; 369: 499-511.
[127]
Honda Y., Juji T., Matsuki K., et al.: HLA-DR2 and Dw2 in narcolepsy and in other disorders of excessive somnolence without cataplexy. Sleep 1986; 9: 133-142.
[128]
Mignot E., Hayduk R., Black J., et al.: HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; 20: 1012-1020.
[129]
Mitler M.M., Carskadon M.A., Czeisler C.A., et al.: Catastrophes, sleep, and public policy: consensus report. Sleep 1988; 11: 100-109.
[130]
Findley L.J., Suratt P.M., Dinges D.F.: Time-on-task decrements in „steer clear” performance of patients with sleep apnea and narcolepsy. Sleep 1999; 22: 804-809.
[131]
Broughton R., Ghanem Q., Hishikawa Y., et al.: Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Can J Neurol Sci 1981; 8: 299-304.
[132]
Thorpy M.: Therapeutic advances in narcolepsy. Sleep Med 2007; 8: 427-440.
[133]
Wise M.S.: Childhood narcolepsy. Neurology 1998; 50: 37-42.
[134]
Rogers A.E., Aldrich M.S., Lin X.: A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep 2001; 24: 385-391.
[135]
Mullington J., Broughton R.: Scheduled naps in the management of daytime sleepiness in narcolepsy-cataplexy. Sleep 1993; 16: 444-456.
[136]
Wise M.S., Arand D.L., Auger R.R., et al.: Treatment of narcolepsy and other hypersomnias of central origin. An American Academy of Sleep Medicine Review. Sleep 2007; 30: 1712-1727.
[137]
Husain A.M., Yancy W.S., Jr., Carwile S.T., et al.: Diet therapy for narcolepsy. Neurology 2004; 62: 2300-2302.
[138]
Littner M., Johnson S.F., McCall W.V., et al.: Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001; 24: 451-466.
[139]
Mitler M.M., Shafor R., Hajdukovich R., et al.: Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986; 9: 260-264.
[140]
Greenhill L.L., Biederman J., Boellner S.W., et al.: A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 503-511.
[141]
Shindler J., Schachter M., Brincat S., et al.: Amphetamine, mazindol, and fencamfamin in narcolepsy. Br Med J (Clin Res Ed) 1985; 290: 1167-1170.
[142]
Mitler M.M., Hajdukovic R., Erman M., et al.: Narcolepsy. J Clin Neurophysiol 1990; 7: 93-118.
[143]
Mitler M.M., Hajdukovic R., Erman M.K.: Treatment of narcolepsy with methamphetamine. Sleep 1993; 16: 306-317.
[144]
Parkes J.D., Dahlitz M.: Amphetamine prescription. Sleep 1993; 16: 201-203.
[145]
Knoll J.: Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl 1983; 95: 57-80.
[146]
Kuran W.: [ Selegiline (Jumex) in the treatment of narcolepsy]. Neurol Neurochir Pol 1993; 27: 131-133.
[147]
Mayer G., Ewert Meier K., Hephata K.: Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 1995; 18: 306-319.
[148]
Reinish L.W., MacFarlane J.G., Sandor P., et al.: REM changes in narcolepsy with selegiline. Sleep 1995; 18: 362-367.
[149]
Boivin D.B., Montplaisir J., Petit D., et al.: Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993; 16: 46-53.
[150]
Billiard M., Besset A., Montplaisir J., et al.: Modafinil: a double-blind multicentric study. Sleep 1994; 17: 107-112.
[151]
Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol 1998; 43: 88-97.
[152]
Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology 2000; 54: 1166-1175.
[153]
Dinges D.F., Arora S., Darwish M., et al.: Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006; 22: 159-167.
[154]
Harsh J.R., Hayduk R., Rosenberg R., et al.: The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006; 22: 761-774.
[155]
Laborit H.: [Correlations between protein synthesis and serotonin in various activities of the central nervous system. (Slow and desynchronized sleep, learning and memory, sexual activity, morphine tolerance, aggressivity, Na gammahydroxybutyrate pharmacology]. Agressologie 1971; 12: 9-23.
[156]
Mamelak M., Escriu J.M., Stokan O.: Sleep-inducing effects of gammahydroxybutyrate. Lancet 1973; 2: 328-329.
[157]
Mamelak M., Webster P.: Treatment of narcolepsy and sleep apnea with gammahydroxybutyrate: a clinical and polysomnographic case study. Sleep 1981; 4: 105-111.
[158]
Broughton R., Mamelak M.: Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can J Neurol Sci 1980; 7: 23-31.
[159]
Scrima L., Hartman P.G., Johnson F.H., Jr., et al.: The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep 1990; 13: 479-490.
[160]
Lammers G.J., Arends J., Declerck A.C., et al.: Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993; 16: 216-220.
[161]
Frenette E., Kushida C.A.: Primary hypersomnias of central origin. Semin Neurol 2009; 29: 354-367.
[162]
Guilleminault C., Raynal D., Takahashi S., et al.: Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 1976; 54: 71-87.
[163]
Shapiro W.R.: Treatment of Cataplexy with Clomipramine. Arch Neurol 1975; 32: 653-656.
[164]
Dauvilliers Y., Billiard M., Montplaisir J.: Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003; 114: 2000-2017.
[165]
Langdon N., Shindler J., Parkes J.D., et al.: Fluoxetine in the treatment of cataplexy. Sleep 1986; 9: 371-373.
[166]
Abad V.C., Guilleminault C.: Emerging drugs for narcolepsy. Expert Opin Emerg Drugs 2004; 9: 281-291.
[167]
Mignot E., Nishino S.: Emerging therapies in narcolepsy-cataplexy. Sleep 2005; 28: 754-763.
[168]
Mieda M., Willie J.T., Hara J., et al.: Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004; 101: 4649-4654.
[169]
John J., Wu M.F., Siegel J.M.: Systemic administration of hypocretin-1 reduces cataplexy and normalizes sleep and waking durations in narcoleptic dogs. Sleep Res Online 2000; 3: 23-28.
[170]
Arias-Carrion O., Murillo-Rodriguez E.: Cell transplantation: a future therapy for narcolepsy? CNS Neurol Disord Drug Targets 2009; 8: 309-314.
[171]
Arias-Carrion O., Drucker-Colin R., Murillo-Rodriguez E.: Survival rates through time of hypocretin grafted neurons within their projection site. Neurosci Lett 2006; 404: 93-97.
[172]
Arias-Carrion O., Murillo-Rodriguez E., Xu M., et al.: Transplantation of hypocretin neurons into the pontine reticular formation: preliminary results. Sleep 2004; 27: 1465-1470.
[173]
Chen W., Black J., Call P., et al.: Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 2005; 58: 489-490.
[174]
Barbier A.J., Berridge C., Dugovic C., et al.: Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol 2004; 143: 649-661.
[175]
Tedford C.E., Phillips J.G., Gregory R., et al.: Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands. J Pharmacol Exp Ther 1999; 289: 1160-1168.
[176]
Riehl J., Honda K., Kwan M., et al.: Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy. Neuropsychopharmacology 2000; 23: 34-45.
[177]
Nishino S., Arrigoni J., Shelton J., et al.: Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narcolepsy. J Neurosci 1997; 17: 6401-6408.
[178]
Broberger C., McCormick D.A.: Excitatory effects of thyrotropin-releasing hormone in the thalamus. J Neurosci 2005; 25: 1664-1673.
Scholar Google
PubMed